Wells Fargo’s Rhythm Pharmaceuticals RYTM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.97M | Sell |
34,108
-38,509
| -53% | -$3.74M | ﹤0.01% | 2980 |
|
|
2025
Q4 | $7.77M | Buy |
72,617
+25,483
| +54% | +$2.7M | ﹤0.01% | 2266 |
|
|
2025
Q3 | $4.76M | Buy |
47,134
+4,766
| +11% | +$442K | ﹤0.01% | 2624 |
|
|
2025
Q2 | $2.68M | Sell |
42,368
-28,270
| -40% | -$1.73M | ﹤0.01% | 2976 |
|
|
2025
Q1 | $3.74M | Buy |
70,638
+33,314
| +89% | +$1.85M | ﹤0.01% | 2643 |
|
|
2024
Q4 | $2.09M | Buy |
37,324
+7,850
| +27% | +$434K | ﹤0.01% | 3162 |
|
|
2024
Q3 | $1.54M | Sell |
29,474
-61
| -0.2% | -$2.92K | ﹤0.01% | 3241 |
|
|
2024
Q2 | $1.21M | Buy |
29,535
+2,550
| +9% | +$102K | ﹤0.01% | 3375 |
|
|
2024
Q1 | $1.17M | Sell |
26,985
-12,774
| -32% | -$559K | ﹤0.01% | 3351 |
|
|
2023
Q4 | $1.83M | Sell |
39,759
-13,950
| -26% | -$440K | ﹤0.01% | 2982 |
|
|
2023
Q3 | $1.23M | Sell |
53,709
-23,385
| -30% | -$524K | ﹤0.01% | 3179 |
|
|
2023
Q2 | $1.27M | Buy |
77,094
+26,291
| +52% | +$475K | ﹤0.01% | 3285 |
|
|
2023
Q1 | $906K | Buy |
50,803
+44,060
| +653% | +$1.11M | ﹤0.01% | 3443 |
|
|
2022
Q4 | $196K | Buy |
6,743
+4,569
| +210% | +$117K | ﹤0.01% | 4183 |
|
|
2022
Q3 | $54K | Sell |
2,174
-6,754
| -76% | -$126K | ﹤0.01% | 4923 |
|
|
2022
Q2 | $37K | Sell |
8,928
-890
| -9% | -$4.87K | ﹤0.01% | 5165 |
|
|
2022
Q1 | $113K | Sell |
9,818
-11,325
| -54% | -$99.4K | ﹤0.01% | 5265 |
|
|
2021
Q4 | $210K | Buy |
21,143
+18,930
| +855% | +$213K | ﹤0.01% | 5234 |
|
|
2021
Q3 | $29K | Sell |
2,213
-7,558
| -77% | -$115K | ﹤0.01% | 5837 |
|
|
2021
Q2 | $191K | Sell |
9,771
-11,292
| -54% | -$234K | ﹤0.01% | 5048 |
|
|
2021
Q1 | $448K | Sell |
21,063
-10,218
| -33% | -$296K | ﹤0.01% | 4742 |
|
|
2020
Q4 | $930K | Buy |
31,281
+14,256
| +84% | +$362K | ﹤0.01% | 4085 |
|
|
2020
Q3 | $369K | Sell |
17,025
-4,481
| -21% | -$103K | ﹤0.01% | 4570 |
|
|
2020
Q2 | $480K | Buy |
21,506
+6,492
| +43% | +$127K | ﹤0.01% | 4353 |
|
|
2020
Q1 | $229K | Sell |
15,014
-8,292
| -36% | -$148K | ﹤0.01% | 4601 |
|
|
2019
Q4 | $535K | Buy |
23,306
+12,010
| +106% | +$267K | ﹤0.01% | 4309 |
|
|
2019
Q3 | $244K | Buy |
11,296
+4,561
| +68% | +$97.9K | ﹤0.01% | 4844 |
|
|
2019
Q2 | $148K | Sell |
6,735
-1,527
| -18% | -$38.6K | ﹤0.01% | 5130 |
|
|
2019
Q1 | $226K | Buy |
8,262
+626
| +8% | +$18K | ﹤0.01% | 4757 |
|
|
2018
Q4 | $205K | Buy |
7,636
+2,047
| +37% | +$56.6K | ﹤0.01% | 4884 |
|
|
2018
Q3 | $163K | Buy |
5,589
+789
| +16% | +$24.9K | ﹤0.01% | 5115 |
|
|
2018
Q2 | $150K | Buy |
4,800
+199
| +4% | +$5.44K | ﹤0.01% | 5178 |
|
|
2018
Q1 | $92K | Buy |
4,601
+86
| +2% | +$2.28K | ﹤0.01% | 5343 |
|
|
2017
Q4 | $131K | Buy |
+4,515
| New | +$119K | ﹤0.01% | 5187 |
|
Other funds holding RYTM
RCM
BBA
VPM
VCM
PA
Wells Fargo's RYTM Position: Q1 2026 in Review
Wells Fargo reduced its Rhythm Pharmaceuticals (RYTM) stake by 53% in Q1 2026, selling an estimated $3.74M and leaving 34,108 shares worth $2.97M. The position accounts for ﹤0.01% of the portfolio, ranked #2980.
Wells Fargo first reported a position in RYTM in Q4 2017 and has held it in 34 quarters since. The position peaked at $7.77M in Q4 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.
- Wells Fargo held 34,108 shares of Rhythm Pharmaceuticals worth $2.97M as of Q1 2026.
- Wells Fargo sold 38,509 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $3.74M.
- Rhythm Pharmaceuticals made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #2980 holding.
- Wells Fargo first reported a position in Rhythm Pharmaceuticals in Q4 2017 and has held it in 34 quarters since.
- Wells Fargo's Rhythm Pharmaceuticals position peaked at $7.77M in Q4 2025.
- 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.
Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.